Poziotinib Drug Asset Due Diligence Report 2026

This Poziotinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Poziotinib can convert its Small molecule drug profile and EGFR exon 20 x HER2 exon 20 x HER4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Poziotinib (query alias: poziotinib)
Modality / target	Small molecule drug; EGFR exon 20 x HER2 exon 20 x HER4; EGFR exon 20 inhibitors, HER2 exon 20 inhibitors, HER4 antagonists
Highest global status	Phase 2
Originator	Hanmi Pharmaceutical Co., Ltd.
Active developers	Luye Pharma Group Ltd., Hanmi Pharmaceutical Co., Ltd., Spectrum Pharmaceuticals, Inc.

The MCP disease footprint includes Head and Neck Neoplasms, Lung Cancer, Stomach Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05378763	Phase 3	Suspended	268	Progression Free Survival (PFS)
NCT05045404	Phase 2	Withdrawn	Not disclosed	Progression-free survival
NCT04402008	Phase 1/2	Terminated	42	Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2; n=42; evaluation: not stated. Reported fields: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) = 1 Participants ; -; -

A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

Phase 2; n=1; evaluation: not stated. Reported fields: -; -; -

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.

Phase 2; n=203; evaluation: Positive. Reported fields: -; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Poziotinib addresses Head and Neck Neoplasms, Lung Cancer, Stomach Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-05-03	Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center	Clinical	Financial terms not disclosed
2015-03-04	Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in Several Solid Tumors, From Hanmi Pharmaceuticals	Phase 2	Financial terms not disclosed
2014-08-22	Luye In-Licenses China Rights To Cancer Drug From Korea's Hanmi Pharmaceutical, Co., Ltd	Phase 2	US$20.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of non-small cell lung cancer with poziotinib”. The milestone feed surfaced a patent-application signal described as “Methods of treating cancer with poziotinib”. The milestone feed surfaced a patent-application signal described as “TRATAMIENTO CON POZIOTINIB PARA EL CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO